Boston Scientific Co. (NYSE:BSX) Shares Acquired by Tandem Capital Management Corp ADV

Tandem Capital Management Corp ADV boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 0.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 58,351 shares of the medical equipment provider’s stock after buying an additional 485 shares during the period. Boston Scientific comprises about 2.7% of Tandem Capital Management Corp ADV’s portfolio, making the stock its 7th biggest holding. Tandem Capital Management Corp ADV’s holdings in Boston Scientific were worth $4,890,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. HWG Holdings LP lifted its holdings in Boston Scientific by 3.0% in the 3rd quarter. HWG Holdings LP now owns 6,448 shares of the medical equipment provider’s stock worth $540,000 after purchasing an additional 186 shares during the last quarter. Mount Yale Investment Advisors LLC raised its position in shares of Boston Scientific by 7.4% in the third quarter. Mount Yale Investment Advisors LLC now owns 16,794 shares of the medical equipment provider’s stock valued at $1,407,000 after purchasing an additional 1,159 shares during the period. Dakota Wealth Management lifted its stake in shares of Boston Scientific by 14.8% in the third quarter. Dakota Wealth Management now owns 57,795 shares of the medical equipment provider’s stock worth $4,843,000 after buying an additional 7,455 shares during the last quarter. Zweig DiMenna Associates LLC boosted its holdings in shares of Boston Scientific by 42.3% during the 3rd quarter. Zweig DiMenna Associates LLC now owns 271,000 shares of the medical equipment provider’s stock worth $22,710,000 after buying an additional 80,500 shares during the period. Finally, Values First Advisors Inc. bought a new stake in shares of Boston Scientific during the 3rd quarter worth $28,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the transaction, the executive vice president now directly owns 37,468 shares in the company, valued at approximately $3,061,135.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Joseph Michael Fitzgerald sold 132,527 shares of Boston Scientific stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the sale, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the transaction, the executive vice president now owns 37,468 shares in the company, valued at $3,061,135.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 316,253 shares of company stock valued at $26,714,298 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Price Performance

Shares of NYSE BSX traded down $1.35 during mid-day trading on Friday, hitting $83.75. 657,858 shares of the stock were exchanged, compared to its average volume of 6,019,053. The company has a market cap of $122.87 billion, a P/E ratio of 71.52, a PEG ratio of 2.87 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. Boston Scientific Co. has a twelve month low of $49.15 and a twelve month high of $88.79. The stock’s fifty day simple moving average is $83.19 and its two-hundred day simple moving average is $77.57.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The business’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.50 EPS. As a group, analysts forecast that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on BSX shares. Wells Fargo & Company boosted their target price on shares of Boston Scientific from $87.00 to $98.00 and gave the stock an “overweight” rating in a research report on Thursday. Raymond James increased their target price on Boston Scientific from $91.00 to $94.00 and gave the company a “strong-buy” rating in a research note on Wednesday, September 4th. Royal Bank of Canada raised their target price on Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft increased their price objective on Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a research report on Thursday, July 25th. Finally, Bank of America boosted their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $93.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.